why choose us

First received: July 20, 2022

Clinical Trial: A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

Study Status: Completed

Recruit Status: Completed

Condition: Healthy
Renal Insufficiency

Study Type: Interventional


Official Title: A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of LOXO-292

Brief Summary: The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. The study will last up to 9 days, excluding screening.

Read more